Sex | Pathway | Effective /total size | # ↓ genes | Contributing genes | P-value |
---|---|---|---|---|---|
Girls | |||||
 | mRNA Processinga | 124/126 | 32 | PTBP2↑; SRSF1↑; SFPQ↑; SNRNP40↑; CELF1↑; HNRNPU↑; TRA2B↑; SRSF6↑; HNRNPH1↑; PRPF40A↑ | 1.9E-03 |
Ephrin signaling | 16/22 | 5 | NCK2↑; SDCBP↑; ARHGEF7↑ | 8.4E-03 | |
Ectoderm Commitment Pathwaya | 87/129 | 30 | PDE7A↑; SDCBP↑; MZF1↑; C1GALT1↑ NF2↑; OGT↑; TSC22D1↑ | 9.1E-03 | |
IL-4 Signaling Pathwaya | 52/53 | 27 | IKBKB↑; PTPN11↑; IL2RG↓; ATF2↑; RPS6KB1↑ | 1.3E-02 | |
Physiological and Pathological Hypertrophy of the Hearta | 20/24 | 8 | IL6ST↑; CAMK2D↑; PPP3CB↑ | 1.6E-02 | |
miR-targeted genes in lymphocytes - TarBase | 362/482 | 108 | Top 5 out of 17 genes: MBNL1↑; SUCLG2↑; TGFBR2↑; GTPBP3↑; DMTF1↑ | 1.9E-02 | |
Basal transcription factors - Homo sapiens (human)a | 39/45 | 13 | TAF8↑; GTF2H2C_2↑; TAF1↑; TAF11↑ | 2.1E-02 | |
Spliceosome - Homo sapiens (human)a | 127/130 | 33 | HNRNPU↑; PRPF40A↑; RBM25↑; SNRNP40↑; THOC1↑; SRSF1↑; SRSF6↑; TRA2B↑ | 2.2E-02 | |
Activated TLR4 signalinga | 110/120 | 47 | ATF2↑; SIGIRR↑; IL6ST↑; PTPN11↑; IKBKB↑; IRF3↑; UBE2D3↑ | 2.9E-02 | |
Insulin Pathway | 44/47 | 13 | RPS6KB1↑; PTPN11↑; NCK2↑; EXOC7↑ | 3.0E-02 | |
Salmonella infection - Homo sapiens (human) | 68/86 | 38 | PFN1↓; RAB7A↓; DYNC1H1↑; WAS↓; PKN2↑ | 3.7E-02 | |
Amphetamine addiction - Homo sapiens (human)a | 48/68 | 21 | PPP3CB↑; CAMK2D↑; ATF4↑; ATF2↑ | 4.0E-02 | |
Generic Transcription Pathway | 367/478 | 91 | Top 5 out of 16 genes: ZNF625↑; ZNF37A↑; ZNF419↑; ZNF205↓; ZNF12↑ | 4.0E-02 | |
Direct p53 effectorsa | 123/147 | 47 | PMS2↑; KAT2A↑; BNIP3L↑; TGFA↓; PIDD1↑; AIFM2↑; HIC1↓ | 4.9E-02 | |
Boys | |||||
 | Lidocaine (Local Anaesthetic) Action Pathwaya | 19/31 | 13 | CYP3A4↓; CACNA2D2↓; ATP1A4↑; ATP1B1↑; ATP1B3↑; ADRA1A↓ | 9.9E-04 |
Signaling events mediated by PRLa | 20/23 | 4 | CDK2↑; BCAR1↓; RABGGTA↑; PTP4A3↑; ROCK1↑; ITGB1↑ | 1.3E-03 | |
Protein processing in endoplasmic reticulum - Homo sapiens (human)a | 156/168 | 36 | Top 5 out of 19 significant genes: ATF4↑; SEC31A↑; UBQLN3↓; UGGT1↑; CRYAB↓ | 6.2E-03 | |
Basigin interactionsa | 19/30 | 6 | ATP1B3↑; SLC3A2↑; ATP1B1↑; CAV1↓; ITGB1↑ | 6.3E-03 | |
Morphine Action Pathwaya | 27/44 | 16 | DNAJB11↑; CACNA2D2↓; ATP1A4↑; ATP1B1↑; ATP1B3↑; ADRA1A↓ | 6.9E-03 | |
mRNA Splicing - Major Pathwaya | 116/131 | 14 | Top 5 out of 15 significant genes: SMC1A↑; PCBP1↑; PRPF8↑; SNRPA↓; CD2BP2↑ | 8.3E-03 | |
Validated transcriptional targets of AP1 family members Fra1 and Fra2 | 30/37 | 11 | ATF4↑; TXLNG↑; LAMA3↓; NFATC3↑; USF2↑; CDKN2A↓ | 1.2E-02 | |
Maturity onset diabetes of the young - Homo sapiens (human) | 15/25 | 14 | NR5A2↓; PAX4↓; FOXA2↓; GCK↓ | 1.4E-02 | |
Hedgehog ligand biogenesisa | 15/21 | 5 | OS9↑; DISP2↓; P4HB↑; VCP↑ | 1.4E-02 | |
Salivary secretion - Homo sapiens (human)a | 60/90 | 28 | ADCY3↓; ADRA1A↓; NOS1↓; GUCY1A3↑; PRH2↓; ATP1A4↑; ATP1B1↑; ATP1B3↑; ATP2B3↓ | 1.5E-02 | |
Processing of Capped Intron-Containing Pre-mRNAa | 147/162 | 18 | Top 5 out of 17 significant genes: SMC1A↑; RANBP2↑; PCBP1↑; PRPF8↑; SNRPA↓ | 1.5E-02 | |
G. alpha (s) signaling eventsa | 81/129 | 44 | ADCYAP1R1↓; CALCA↓; PTH2↓; ADCY3↓; GNAZ↓; TSHB↓; INSL3↓; TAAR2↓; GHRHR↓; GLP2R↓; GNG13↓ | 1.6E-02 | |
Neuroactive ligand-receptor interaction - Homo sapiens (human) | 164/275 | 102 | GABRG2↓; GABRP↓; NTSR2↓; TAAR2↓; TSHB↓; CHRM5↓; ADCYAP1R1↓; GH1↓; GHRHR↓; HTR1B↓; ADRA1A↓; GLP2R↓; THRA↓; ADORA1↓; CHRNA2↓; LPAR1↑; OPRL1↓; GRM5↓ | 2.1E-02 | |
FOXM1 transcription factor network | 34/42 | 10 | CDK2↑; XRCC1↑; CENPF↑; NFATC3↑; TGFA↓; CDKN2A↓ | 2.1E-02 | |
TCA Cycle | 17/17 | 4 | FH↑; MDH2↑; OGDH↑; IDH2↑ | 2.2E-02 |